21 July 2024 : Clinical Research
Cost-Effectiveness Analysis of Hepatic Arterial Chemotherapy for Advanced Hepatocellular Carcinoma in China: A Comparative Analysis of HAIC-FO and Sorafenib
Jie Gao1BCE, Shu Liu2BCE, Shao-Jun Li1BCE, Rui Wang3E, Zeng-Hui Meng1AE, Xiang-Shuo Kong2AE*DOI: 10.12659/MSM.944526
Med Sci Monit 2024; 30:e944526
Table 2 Cost-effectiveness of treatment of HAIC-FO vs sorafenib in the overall population.
| QALYs | Total cost, $ | ICER, $ (per QALY) | |
|---|---|---|---|
| Sorafenib | 0.65 | 18,795 | / |
| HAIC-FO | 1.06 | 22,781 | / |
| Incremental | 0.41 | 3,985 | 9,720 |
| HAIC-FO – hepatic arterial infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin; QALYs – quality-adjusted life-years; ICER – incremental cost-effectiveness ratio. | |||